Clinical Study On Curative Effect Evaluation Of Non - Small Cell Lung Cancer Guided By

Purpose：The object of study is the patients of non-small cell lung cancer.Study the guidance of appearance and spirit theory in different period ofpatients. Study the evaluation of therapeutic efficiency in different periodof patients.Material and method：Toreviewinganalyzethe317patientsofnon-smallcelllung cancer. To investigate and analyze the general data and conditions ofpatients. To investigate the meaning of appearance and spirit. To investigatethe condition of treating and the guidance of appearance and spirit relativelyunified hypothesis in the treating of non-small cell lung cancer. The patientsare divided into three parts. One is the stage of prevention of recurrence andmetastasis. The second is the stage of survival. The third is the stage of dyingearly. The patients in the stage of prevention of recurrence and metastasis arein the stage of non-tumor, whose tumor are cut off by operation. The patientsin the stage of survival are in the stage of tumor, who are recurrence, ormetastasis, or primary tumor. The patients in the stage of dying early,whoare died in my hospital. The patients in the stage of survival are divided intotwo parts. One is early stage in the stage of survival. The other is later stagein the stage of survival. The patients in the early stage of survival are withprimary lung cancer,or lung metastasis, or bone metastasis,or lymph nodemetastasis. The patients in the later stage of survival are with other organsmetastasis except lung, such as liver metastasis, brain metastasis, kidneymetastasis, pleural effusion,etc. According whether the progression ofdisease, chemotherapy and the times of chemotherapy the patients of the twostages are divided into three groups. The three groups are non-chemotherapy group,one-chemotherapy group and two-group chemotherapy group. The patients innon-chemotherapy group are not treated by chemotherapy after the disease progressed. The patients in one-chemotherapy are treated by one scheme ofchemotherapy after the disease progressed. The patients in two-chemotherapy aretreated by two or up two scheme of chemotherapy after the disease progressed.Tocompare the appearance and spirit of the three groups. That are medianprogression free survival and clinical symptoms of therapeutic efficiency, thescore of KPS. According to chemotherapy in six months before death the patientsin the stage of dying early are divided into two groups. The two groups arenon-chemotherapy group and chemotherapy group. The patients in thenon-chemotherapy group are not treated by chemotherapy in six months before death.The patients in the chemotherapy group are treated by chemotherapy in six monthsbefore death. To compare the appearance and spirit of the two groups. That areoverall survival time and clinical symptoms of therapeutic efficiency. The dataare entered by Access2007. The data are statistical treated by spss19.0.Results：There are317patients in the clinical research. The number of maleis192. The number of female is125.The ratio of male to female is1.536:1. Theaverage age is65.86±11.54years old. The maximum age is89years old. Theminimum age is30years old. There are118patients with smoking history,occupying37.22%. In the317patients, there are34patients in the stage ofprevention of recurrence and metastasis, occupying10.73%. In the317patients,there are179patients in the stage of survival, occupying56.47%. In the317patients, there are104patients in the dying early, occupying32.80%. Thestation of disease include TNM staging of lung cancer when diagnosed,histological type, the symptom of traditional Chinese medicine, the station ofmetastasis, the score of KPS. When the lung cancer is diagnosed, there are25patients in the I stage of TNM. There are27patients in the II stage of TNM.There are46patients in the III stage of TNM. There are219patients in theIV stage of TNM. The histological type of232patients is adenocarcinoma. Thehistological type of81patients is squamous cell carcinoma. The histologicaltype of4patients is other types. There are65patients in the score of KPS below30. There are57patients in the score of KPS below40. There are55patientsin the score of KPS below50. There are51patients in the score of KPS below60. There are89patients in the score of KPS up70. There are115patients inthe type of deficiency of qi and yin.The rules of appearance: The damage of appearance is aggravating from thestage of prevention of recurrence and metastasis to the stage of dying early.The laboratory tests of the stage of prevention of recurrence and metastasisis normal. There are136patients（75.98%）in the stage of survival are abnormal.There are101patients（97.12%）in the stage of dying early are abnormal. Therules of spirit: The score of KPS is73.82of the stage of prevention of recurrenceand metastasis. The score of KPS is56.98of the stage of survival. The scoreof KPS is35.48of the stage of dying early. The score of clinical symptoms is5.06of the stage of prevention of recurrence and metastasis. The score of KPSis8.99of the stage of survival. The score of KPS is15.24of the stage of dyingearly. The rules of treating appearance: The methods of treating appearance are4.7of the stage of prevention of recurrence and metastasis. The methods oftreating appearance are4.17of the stage of survival. The methods of treatingappearance are3.28of the stage of dying early. The rules of treating spirit:The methods of treating spirit are3.85of the stage of prevention of recurrenceand metastasis. The methods of treating spirit are5.28of the stage of survival.The methods of treating spirit are6.68of the stage of dying early.The median progression free survival is five months of the non-chemotherapygroup in the early stage of survival. The median progression free survival bothare nine months of the one-chemotherapy group and the two-chemotherapy groupin the stage of survival. There are statistical significance between thenon-chemotherapy group and the one-chemotherapy group, the two-chemotherapygroup（p<0.05）. There are not statistical significance between theone-chemotherapy group and the two-chemotherapy group（p>0.05）. There are notstatistical significance between the non-chemotherapy group and theone-chemotherapy group, the two-chemotherapy group in the score of KPS and the score of clinical symptoms（p>0.05）. The median progression free survival issix months of the non-chemotherapy group in the later stage of survival. Themedian progression free survival is five months of the one-chemotherapy group.The median progression free survival is four months of the two-chemotherapy group.here are not statistical significance between them（p>0.05）. There arestatistical significance between the non-chemotherapy group and theone-chemotherapy group, the two-chemotherapy group in the score of KPS and thescore of clinical symptoms（p<0.05）.But there are not statistical significancebetween the one-chemotherapy group and the two-chemotherapy group in the scoreof KPS and the score of clinical symptoms（p>0.05）. The median overall survivaltime is eleven months of the non-chemotherapy group in the stage of dying early.The median overall survival time is ten months of the chemotherapy group in thestage of dying early. There are not statistical significance between them（p>0.05）.By <2013the rule of effect to combination traditional Chinesemedicine and western medicine treating advanced tumor>, the patients in thechemotherapy group and non-chemotherapy group are scored of clinical symptomsin the first days and the14th days after in hospital. And the pain index arecalculated, the curative effect are judged. The significant efficiency of thepain index of the non-chemotherapy group(57.69%) is higher than the chemotherapygroup(38.46) in the14th days after in hospital. The pain index is related tothe clinical symptoms and frequency of symptoms.Conclusion：In the early stage of disease the treating key is appearance.The goal is absolute unity of appearance and spirit. The evaluation focus arecomplete remission and symptoms disappearing. In the later stage of disease thetreating key is spirit. The goal is relative unity of appearance and spirit.The evaluation focus are less symptoms. There is no related to the tumor. Thegoal of the early stage in the middle stage is the same to the early stage. Thetreating key is appearance. The goal is absolute unity of appearance and spirit.The evaluation focus are complete remission and symptoms disappearing. And the goal of the later stage in the middle stage is the same to the later stage. Thetreating key is spirit. The goal is relative unity of appearance and spirit.The evaluation focus are less symptoms. There is no related to the tumor.